María Molina Molina-rekin lankidetzan egindako argitalpenak (7)

2024

  1. Influence of Clinical Practice Guidelines on the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Data from the Registry of the Spanish Society of Pulmonology and Thoracic Surgery

    Open Respiratory Archives, Vol. 6, Núm. 3

2023

  1. Impact of COVID-19 Infection on Patients with Preexisting Interstitial Lung Disease: A Spanish Multicentre Study

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 273-276

  2. Persistent Respiratory Failure and Re-Admission in Patients with Chronic Obstructive Pulmonary Disease Following Hospitalization for COVID-19

    International Journal of COPD, Vol. 18, pp. 2473-2481

2022

  1. Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity

    Archivos de Bronconeumologia, Vol. 58, Núm. 2, pp. 135-141

2020

  1. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

    The Lancet Respiratory Medicine, Vol. 8, Núm. 5, pp. 453-460

2019

  1. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

    The Lancet Respiratory Medicine, Vol. 7, Núm. 9, pp. 771-779

2018

  1. Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis

    Expert Review of Respiratory Medicine